Featured Research

from universities, journals, and other organizations

Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's

Date:
August 20, 2014
Source:
Houston Methodist
Summary:
Patients with mild to moderate Alzheimer’s disease currently have no treatment options to slow brain cell deterioration. Researchers are studying an investigational drug that proposes to do just that.

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that.

Related Articles


T-817MA focuses on preventing brain cell loss and slowing disease progression, whereas current treatment options including Donepezil (Ariceptฎ), Rivastigmine (Exelonฎ), and Memantine (Namenda™) merely treat the symptoms of mild to moderate Alzheimer's. The researchers want to know whether the investigational therapy using T-817MA can prevent brain cell loss, slowing disease progression in a more fundamental way.

Houston Methodist is the only study location in Texas to offer this randomized, double-blind, placebo-controlled study. Approximately two-thirds of study participants will receive active study drug, but neither the patient nor the study personnel will know whether patients received the active study drug or placebo until the patients' participation in the study is complete. This is a Phase II clinical trial, an early study assessing the efficacy of a drug that has been tested on relatively few research subjects.

"Previous studies in mice have shown this investigational drug may work by protecting brain cells, which would result in improved memory and cognition," said Joseph C. Masdeu, M.D., Ph.D., principal investigator of this study at Houston Methodist and director of the NNAC. "As someone who sees the devastating impact this disease has on patients and their families, our goal is to find out if this drug is a viable option for our patients."

Of the more than five million Americans living with Alzheimer's disease, almost two-thirds are women. American women are twice as likely to die of Alzheimer's disease as they are from breast cancer. According to the Alzheimer's Association, someone develops Alzheimer's every 67 seconds. In 2013, 15.5 million caregivers provided an estimated 17.7 billion hours of unpaid care valued at more than $220 billion.

People already diagnosed with mild to moderate Alzheimer's may be eligible for this study if they are women or men aged 55-85; they have taken donepezil (Aricept) treatment for at least six months; live in the community, not in a nursing home or assisted-living facility; and have a study partner who has regular contact with the patient (at least 10 hours per week) and can attend study visits.

This study is sponsored by Toyama Chemical Co., Ltd., and is being conducted by the Alzheimer's Disease Cooperative Study (ADCS), the largest Alzheimer's disease therapeutic research consortium in the United States and supported by the National Institute on Aging. Approximately 50 clinical sites nationwide will offer the study to 450 patients with mild to moderate Alzheimer's disease. Houston Methodist expects to enroll approximately 20 patients. For study questions, call 281.222.9983.


Story Source:

The above story is based on materials provided by Houston Methodist. Note: Materials may be edited for content and length.


Cite This Page:

Houston Methodist. "Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's." ScienceDaily. ScienceDaily, 20 August 2014. <www.sciencedaily.com/releases/2014/08/140820105846.htm>.
Houston Methodist. (2014, August 20). Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's. ScienceDaily. Retrieved January 31, 2015 from www.sciencedaily.com/releases/2014/08/140820105846.htm
Houston Methodist. "Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's." ScienceDaily. www.sciencedaily.com/releases/2014/08/140820105846.htm (accessed January 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, January 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) — The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) — President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) — The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) — The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins